Can an experimental injection clear stubborn psoriasis? a new trial aims to find out.
NCT ID NCT07719530
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether the experimental drug SHR-1139 can improve skin clearance in adults with moderate to severe plaque psoriasis. About 60 participants will receive either SHR-1139 or a placebo over 52 weeks. The main goal is to see how many achieve complete skin clearance by week 12.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental drug called SHR-1139
- What this could lead to
- If successful, SHR-1139 could offer a new treatment option for people with moderate to severe plaque psoriasis, potentially leading to clearer skin.
- What could go wrong
- This is an early phase 2 trial with only 60 participants, so results may not apply to everyone. The drug may cause side effects or fail to outperform placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASISOL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dermatology Hospital Hospital of Southern Medical University
Guangzhou, Guangzhou, 510091, China